Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: Even if a patient received more than six cycles of chemotherapy, the study was scheduled to end at a maximum of 28 weeks. Patients were enrolled into the study if they were expected to undergo a minimum of three and a maximum of six (additional) cycles of chemotherapy. However, chemotherapy may have been discontinued earlier as a result of disease progression or toxicity of the chemotherapeutic regimen. Therefore, some patients who did not begin a second cycle of chemotherapy, and thus did not self-administer the first follow-up QoL assessment, may still have completed the epoetin alfa study. In such cases, patients were asked to complete the QoL assessment scheduled for study completion. Because patients could be enrolled with a variable number of expected chemotherapy cycles, and because those cycles could be of varying durations, the timing of QoL assessments could not be standardised to specific days or weeks in the study. The actual timing of the QoL assessments that resulted from this study design is illustrated in Figure 2Figure 2
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. email@example.com